<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477111</url>
  </required_header>
  <id_info>
    <org_study_id>P13-4601</org_study_id>
    <nct_id>NCT02477111</nct_id>
  </id_info>
  <brief_title>European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>A Multicenter, Open Label, Prospective, Post Approval Study of the INCRAFT® Abdominal Aortic Aneurysm (AAA) Stent Graft System in Subjects With Abdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INSIGHT is a postmarket clinical follow-up study in the European Union. The purpose of the&#xD;
      study is to continue to evaluate the safety and effectiveness/performance of INCRAFT in&#xD;
      subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical&#xD;
      practice. Approximately 150 subjects will be enrolled and followed through 5-years post&#xD;
      procedure. Up to 25 sites in Europe may participate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INSIGHT is a postmarket clinical follow-up study in the European Union. The purpose of the&#xD;
      study is to continue to evaluate the safety and effectiveness/performance of INCRAFT in&#xD;
      subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical&#xD;
      practice. Approximately 150 subjects will be enrolled and followed through 5-years&#xD;
      postprocedure. Up to 25 sites in Europe may participate. Subjects will be enrolled and&#xD;
      followed at 1 month and 6 month post-procedure and annually up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Major Adverse Events (MAE) Through 30 Days</measure>
    <time_frame>Within 30-days post-procedure</time_frame>
    <description>MAE rate through 30 days includes Death, Stroke/CVA, Myocardial Infarction, New onset renal failure (requiring dialysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of Major Adverse Events</measure>
    <time_frame>Through 5 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Technical Success at Conclusion of Index Procedure</measure>
    <time_frame>At the conclusion of the index procedure</time_frame>
    <description>successful insertion of the delivery system through the vasculature and successful deployment of the device at the intended location</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Type I or III Endoleak</measure>
    <time_frame>Within 1 year post-procedure</time_frame>
    <description>defined as absence of type I or III endoleaks and absence of aneurysm enlargement (growth &gt;5mm compared to the 1-month size measurement) within 1-year post-procedure as assessed by the core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>InCraft® - AAA Stent Graft System</measure>
    <time_frame>Assessed at 1 year</time_frame>
    <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Absence of Stent Graft Fracture Within 30-days and 1-year Post-procedure</measure>
    <time_frame>Assessed within 30-days and 1-year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Aneurysm Sac Rupture</measure>
    <time_frame>Within 1-year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of INCRAFT® Procedure (Minutes)</measure>
    <time_frame>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</time_frame>
    <description>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Time Fluoroscopy is Used During the Procedure</measure>
    <time_frame>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Contrast Volume Used During the Procedure</measure>
    <time_frame>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular abdominal aortic aneurysm repair</intervention_name>
    <description>Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are eligible for endovascular repair of an abdominal aortic aneurysm&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female age 18 years or older&#xD;
&#xD;
          2. Femoral access vessels should be adequate to fit the selected delivery system&#xD;
&#xD;
          3. Proximal neck length ≥ 10mm&#xD;
&#xD;
          4. Aortic neck diameters ≥ 17mm and ≤ 31mm&#xD;
&#xD;
          5. Aortic neck suitable for suprarenal fixation&#xD;
&#xD;
          6. Infrarenal and suprarenal neck angulation ≤ 60°&#xD;
&#xD;
          7. Iliac fixation length ≥ 15mm&#xD;
&#xD;
          8. Iliac diameters ≥ 7mm and ≤ 22mm&#xD;
&#xD;
          9. Minimum overall AAA treatment length (proximal landing location to distal landing&#xD;
             location) ≥ 128mm&#xD;
&#xD;
         10. Morphology suitable for aneurysm repair&#xD;
&#xD;
         11. Provide written informed consent and as applicable written confidentiality&#xD;
             authorization prior to initiation of study procedures&#xD;
&#xD;
         12. Subject is willing to comply with the specified follow-up evaluation schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has one of the following:&#xD;
&#xD;
               1. Aneurysm sac rupture or leaking abdominal aortic aneurysm&#xD;
&#xD;
               2. Mycotic, dissecting, or inflammatory abdominal aortic aneurysm&#xD;
&#xD;
          2. Known allergy or intolerance to nickel titanium (nitinol), Polyethylene terephthalate&#xD;
             (PET), or polytetrafluoroethylene (PTFE)&#xD;
&#xD;
          3. Known contraindication to undergoing angiography or anticoagulation&#xD;
&#xD;
          4. Existing AAA surgical graft and/or a AAA stent-graft system&#xD;
&#xD;
          5. Women of child bearing potential whom are pregnant, lactating, or planning to become&#xD;
             pregnant during the course of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre Becquemin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 30, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <results_first_submitted>October 9, 2020</results_first_submitted>
  <results_first_submitted_qc>April 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2021</results_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovascular repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited based on physician referral at 25 academic medical centers between 2015 and the last participant was enrolled September 15, 2016</recruitment_details>
      <pre_assignment_details>Of the 154 screened patients, 150 met inclusion criteria were enrolled in the study and 4 were screen fail.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>InCraft® - AAA Stent Graft System</title>
          <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139">All participants who were assessed for one year</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missed visit</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>InCraft® - AAA Stent Graft System</title>
          <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.6" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angina</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arrhythmia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary artery disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percutaneous transluminal coronary angioplasty and/or stent</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary artery bypass grafting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of aneurysm</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transient Ischemic Attack</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carotid endarterectomy/stent</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral arterial disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Moderate renal insufficiency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erectile disfunction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic obstructive pulmonary disease (COPD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other chronic lung disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other relevant medical history</title>
          <description>Other relevant medical history include: Anemia, Aortic Arch Aneurysm, Back Pain, Blindness, Bph, Carotid Occlusion, Depression, Diverticulosis, Dystonia, Gastritis, Gerd, Hernia, Hypogastric Aneurysm, Hypothyroidism, Kidney Stone, Macular Dengeneration, Mononucleosis, Obesity, Pain, Pneumothorax, Posterior L4-L5 Decompression, Prostate Hypertrophy, Renal Artery Stenosis, Renal Insufficiency, Rheumatoid Arthritis, Sleep Apnea, Suspicion Of Intraductal Pancreatic Mucinous Neoplasia, Thrombocytopenia, Varicosis, Wegener's Granulomatosis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Adverse Events (MAE) Through 30 Days</title>
        <description>MAE rate through 30 days includes Death, Stroke/CVA, Myocardial Infarction, New onset renal failure (requiring dialysis)</description>
        <time_frame>Within 30-days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>This is a single arm non-randomized study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Adverse Events (MAE) Through 30 Days</title>
          <description>MAE rate through 30 days includes Death, Stroke/CVA, Myocardial Infarction, New onset renal failure (requiring dialysis)</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurence of Major Adverse Events</title>
        <time_frame>Through 5 years post-procedure</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Technical Success at Conclusion of Index Procedure</title>
        <description>successful insertion of the delivery system through the vasculature and successful deployment of the device at the intended location</description>
        <time_frame>At the conclusion of the index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Technical Success at Conclusion of Index Procedure</title>
          <description>successful insertion of the delivery system through the vasculature and successful deployment of the device at the intended location</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Type I or III Endoleak</title>
        <description>defined as absence of type I or III endoleaks and absence of aneurysm enlargement (growth &gt;5mm compared to the 1-month size measurement) within 1-year post-procedure as assessed by the core lab</description>
        <time_frame>Within 1 year post-procedure</time_frame>
        <population>population analyzed only includes those that are eligible</population>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Type I or III Endoleak</title>
          <description>defined as absence of type I or III endoleaks and absence of aneurysm enlargement (growth &gt;5mm compared to the 1-month size measurement) within 1-year post-procedure as assessed by the core lab</description>
          <population>population analyzed only includes those that are eligible</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" lower_limit="101.085" upper_limit="112.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>InCraft® - AAA Stent Graft System</title>
        <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
        <time_frame>Assessed at 1 year</time_frame>
        <population>population analyzed only includes those that are eligible</population>
        <group_list>
          <group group_id="O1">
            <title>Absence of Stent-graft Migration (&gt;10 mm) Assessed at 1-year</title>
            <description>Absence of stent-graft migration (&gt;10 mm) assessed at 1-year compared to the 1-month size measurement as confirmed by contrast CT-scan or other imaging.</description>
          </group>
        </group_list>
        <measure>
          <title>InCraft® - AAA Stent Graft System</title>
          <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
          <population>population analyzed only includes those that are eligible</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="118.4" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Absence of Stent Graft Fracture Within 30-days and 1-year Post-procedure</title>
        <time_frame>Assessed within 30-days and 1-year post-procedure</time_frame>
        <population>Core lab reported outcome based on received and readable imaging</population>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Absence of Stent Graft Fracture Within 30-days and 1-year Post-procedure</title>
          <population>Core lab reported outcome based on received and readable imaging</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Aneurysm Sac Rupture</title>
        <time_frame>Within 1-year post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absence of Stent-graft Migration (&gt;10 mm) Assessed at 1-year</title>
            <description>Absence of stent-graft migration (&gt;10 mm) assessed at 1-year compared to the 1-month size measurement as confirmed by contrast CT-scan or other imaging.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Aneurysm Sac Rupture</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of INCRAFT® Procedure (Minutes)</title>
        <description>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</description>
        <time_frame>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>This is a single arm non-randomized study.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of INCRAFT® Procedure (Minutes)</title>
          <description>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="39.4" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Time Fluoroscopy is Used During the Procedure</title>
        <time_frame>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>This is a single arm non-randomized study.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Time Fluoroscopy is Used During the Procedure</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="15.9" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Contrast Volume Used During the Procedure</title>
        <time_frame>Duration of INCRAFT procedure is from bifurcate insertion to completion of angiography</time_frame>
        <group_list>
          <group group_id="O1">
            <title>InCraft® - AAA Stent Graft System</title>
            <description>This is a single arm non-randomized study.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Contrast Volume Used During the Procedure</title>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="92.0" upper_limit="106.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected from index procedure until completion of study or early termination</time_frame>
      <desc>All-cause mortality, Serious Adverse Events, other (Not including serious) Adverse Events</desc>
      <group_list>
        <group group_id="E1">
          <title>1 Year</title>
          <description>Single Arm EVAR Subjects who underwent procedure for the implant of InCraft® - AAA Stent Graft System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (including cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Product issues</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Number of participants at risk my vary depending on varying windows used for analysis, imaging availability, visits completed and will therefore not be consistent throughout report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Katherine Braun, Clinical Project Manager</name_or_title>
      <organization>Cordis, A Cardinal Health Company</organization>
      <phone>602-622-9133</phone>
      <email>katherine.braun@cardinalhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

